Mark Cannon - AHC - Virology, University of Minnesota
Gold University of Minnesota M. Skip to main content.University of Minnesota.
Driven to Discover.
Institute for Molecular Virology
What's Inside


IMV Home

  Home > Investigators > Core Investigators > Mark Cannon
 

Mark Cannon

Assistant Professor

Infectious Diseases, Department of Medicine

Email: canno101@umn.edu

Education

MD, Johns Hopkins School of Medicine, 1993

PhD, Wolfson Institute for Biomedical Research, University College, London, 2006

Selected Recent Publications

  • Cannon, M., Cesarman, E., Boshoff, C. 2006. The KSHV G protein-coupled receptor inhibits lytic gene transcription in primary effusion lymphoma cells via a p21-mediated inhibition of Cdk2. Blood 107(1), 277-284.
  • Tyson V. Sharp, Fernando Munoz, Dimitra Bourboulia, Nadege Presneau, Eva Darai, Hsei-Wei Wang, Mark Cannon, David N. Butcher, Andrew G. Nicholson, George Klein, Stephan Imreh, and Chris Boshoff. 2004. LIM domains-containing protein 1 (LIMD1), a tumor suppressor encoded at chromosome 3p21.3, binds pRB and represses E2F-driven transcription PNAS 101, 16531-16536.
  • Cannon, M. & Cesarman, E. 2004. The KSHV G protein-coupled receptor signals via multiple pathways to induce transcription factor activation in primary effusion lymphoma cells. Oncogene 23(2), 514-523.
  • Cannon, M., Philpott, N. J. & Cesarman, E. 2003. The Kaposi's Sarcoma-Associated Herpesvirus G Protein-Coupled Receptor Has Broad Signaling Effects in Primary Effusion Lymphoma Cells. J Virol 77, 57-67.
  • Cannon M, Cesarman E. 2000. Kaposi?s Sarcoma-Associated Herpes Virus and Acquired Immunodeficiency Syndrome-Related Malignancy. Seminars in Oncology 27(4), 409-419.
  • Kazanjian P, Locke A, Hossler P, Lane B, Cannon M, Meshnick SR. 1998. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients. AIDS 12(8), 873-878.


Feedback | Notice of Privacy Practices